Organic compounds

Patent metadata

Field	Value
Publication number	US-9745300-B2
Application number	US-201515301895-A
Country	US
Kind code	B2
Filing date	Apr 3, 2015
Priority date	Apr 4, 2014
Publication date	Aug 29, 2017
Grant date	Aug 29, 2017

Abstract

The invention relates to particular substituted heterocycle fused gamma-carbolines, their prodrugs, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving 5-HT2A receptor, serotonin transporter (SERT) and/or pathways involving dopamine D1/D2 receptor signaling systems, and/or the treatment of residual symptoms.

First claim

The invention claimed is:

1. A compound of formula I:

wherein:
X is N(H), N(R 5 ) or O;
R 5 is C 1-6 alkyl, optionally substituted with D;
R 3 and R 4 are each independently H or D;
R 6 is H or D;
R 1 is H, or
C 1-6 alkyl, optionally substituted with D, or
a pharmaceutically acceptable and physiologically labile moiety,

wherein D is deuterium,
and provided that at least one of R 1 , R 2 , R 3 , R 4 , R 5 , or R 6 includes at least one D;

in free or salt form.

2. The compound according to claim 1 , wherein said compound is a compound of Formula I-B:

wherein:
X is N(H), N(R 5 ) or O;
R 5 is C 1-6 alkyl;
R 1 is H, or
C 1-6 alkyl, or
a pharmaceutically acceptable and physiologically labile moiety,

and wherein D is deuterium.

3. The compound according to claim 1 , wherein R 1 is H.

4. The compound according to claim 1 , wherein R 1 is C 1-6 alkyl.

5. The compound according to claim 1 , wherein R 1 is C 1-6 alkyl optionally substituted with D.

6. The compound according to claim 1 , wherein R 1 is CH 3 .

7. The compound according to claim 1 wherein R 1 is CD 3 .

8. The compound according to claim 1 , wherein R 1 is a pharmaceutically acceptable and physiologically labile moiety.

9. The compound according to claim 1 , wherein R 1 is —C(O)—R 2 , and wherein R 2 is C 1-21 alkyl.

10. The compound according to claim 1 , wherein R 1 is —C(O)—R 2 , and wherein R 2 is C 1-15 alkyl.

11. The compound according to claim 1 , wherein R 1 is —C(O)—R 2 , and wherein R 2 is C 1-9 alkyl.

12. The compound according to claim 1 , wherein R 1 is —C(O)—R 2 , and wherein R 2 is methyl, ethyl or propyl.

13. The compound according to claim 1 , wherein R 1 is —C(O)—R 2 , and wherein R 2 is methyl.

14. The compound according to claim 1 , wherein X is N(H) or N(R 5 ).

15. The compound according to claim 1 , wherein X is O.

16. The compound according to claim 1 , wherein X is N(H).

17. The compound according to claim 1 , wherein X is N(R 5 ), and wherein R 5 is C 1-4 alkyl.

18. The compound according to claim 1 , wherein X is N(R 5 ), and wherein R 5 is CH 3 .

19. The compound according to claim 1 , wherein X is N(R 5 ), and wherein R 5 is CD 3 .

20. The compound according to claim 1 , wherein R 3 is D.

21. The compound according to claim 1 , wherein R 4 is D.

22. The compound according to claim 1 , wherein R 3 and R 4 are D.

23. The compound according to claim 1 , wherein X is N(R 5 ), and R 5 is CD 3 and R 3 and R 4 are both D.

24. The compound according to claim 1 , wherein the Compound is:

25. The compound according to claim 1 , wherein the Compound is:

26. The compound according to claim 1 , wherein the Compound is:

27. The compound according to claim 1 , wherein said compound is in salt form.

28. The compound according to claim 27 , wherein the salt is selected from a group consisting of toluenesulfonic, fumaric and phosphoric acid addition salt.

29. A pharmaceutical composition comprising a compound according to claim 1 , in free or pharmaceutically acceptable salt form, in combination or association with a pharmaceutically acceptable diluent or carrier.

30. A method for the treatment of a central nervous system disorder comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition according to claim 29 , wherein said disorder is selected from a group consisting of obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, agitation, agitation in dementia, agitation in autism and related autistic disorders, gastrointestinal disorders, dysfunction of the gastrointestinal tract motility, post-traumatic stress disorder, impulse control disorders, and intermittent explosive disorder.

31. The method according to claim 30 , wherein said disorder is one or more disorders associated with dementia, selected from disorders associated with mild cognition impairment and dementing illnesses including senile dementia, Alzheimer's disease, Pick's disease, fronto-temporal dementia, parasupranuclear palsy, dementia with Lewy bodies, vascular dementia, Huntington's disease, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, Down syndrome, elderly depression, Wernicke-Korsakoff s syndrome, cortico-basal degenerations and prion disease, autism, and attention deficit hyperactivity disorder.

32. The method according to claim 30 , wherein said disorder is a disorder involving one of the serotonin 5-HT 2A , dopamine D2 and/or serotonin reuptake transporter (SERT) pathways.

33. The method according to claim 30 , wherein the central nervous system disorder is residual symptoms of psychosis, in a patient suffering from schizophrenia, delusional disorder, major depression with psychosis, bipolar disorder with psychotic symptoms, brief psychotic disorder, schizophreniform disorder, schizoaffective disorder, or psychosis caused by a medical condition or substance use.

34. The method according to claim 33 , wherein said residual phase symptoms are selected from negative symptoms such as blunted affect, emotional withdrawal, poor rapport, passive or apathetic social withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation and stereotyped thinking; general psychopathology symptoms such as somatic concern, anxiety, guilt feelings, tension, mannerisms and posturing, depression, motor retardation, uncooperativeness, unusual thought content, disorientation, poor attention, lack of judgment and insight, disturbance of volition, poor impulse control, preoccupation and active social avoidance; cognitive impairment and sleep disorders.

35. The method according to claim 30 , further comprising the administration of one or more other therapeutic agents such as an additional antipsychotic agents and/or anti-depressive agents and/or hypnotic agents.

36. The method of claim 35 , wherein the one or more other therapeutic agents are selected from anti-depressive agents such as compounds that modulate GABA activity, a GABA-B agonist, a 5-HT modulator, a melatonin agonist, an ion channel modulator, a serotonin-2 antagonist/reuptake inhibitor (SARIs), an orexin receptor antagonist, an H3 agonist, a noradrenergic antagonist, a galanin agonist, a CRH antagonist, human growth hormone, a growth hormone agonist, estrogen, an estrogen agonist, a neurokinin-1 drug; and antipsychotic agents, in free or pharmaceutically acceptable salt form.

37. The method according to claim 35 , wherein the one or more other therapeutic agents are antipsychotic agents se

Assignees

• Intra Cellular Therapies Inc

Inventors

• Mates Sharon
• Li Peng
• Wennogle Lawrence P
• Davis Robert

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P25/24

  Antidepressants · CPC title

• A61P25/22

  Anxiolytics · CPC title